Astec Lifesciences Ltd
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.
Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).[1] [2] [3]
- Market Cap ₹ 1,863 Cr.
- Current Price ₹ 951
- High / Low ₹ 1,488 / 635
- Stock P/E
- Book Value ₹ 120
- Dividend Yield 0.00 %
- ROCE -12.6 %
- ROE -44.6 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 4.12% over last quarter.
Cons
- Stock is trading at 7.94 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -6.11% over past five years.
- Company has a low return on equity of -14.1% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Part of BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
207 | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | |
171 | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | 448 | |
Operating Profit | 35 | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 | -66 |
OPM % | 17% | 20% | 14% | 21% | 19% | 18% | 16% | 20% | 23% | 12% | -1% | -17% |
-0 | -16 | 4 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | |
Interest | 9 | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 |
Depreciation | 15 | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 |
Profit before tax | 11 | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 |
Tax % | 22% | -17% | 59% | 33% | 37% | 36% | 23% | 27% | 26% | 27% | -24% | -4% |
9 | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | |
EPS in Rs | 4.68 | 7.60 | 2.55 | 9.80 | 17.87 | 18.28 | 24.28 | 33.21 | 45.85 | 13.04 | -23.93 | -68.71 |
Dividend Payout % | 21% | 16% | -0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | -6% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | 4% |
5 Years: | -6% |
3 Years: | -17% |
TTM: | -17% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -188% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 3% |
3 Years: | -20% |
1 Year: | -30% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 0% |
3 Years: | -14% |
Last Year: | -45% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
Reserves | 95 | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 | 215 |
83 | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | 555 | |
88 | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | 92 | |
Total Liabilities | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 |
132 | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 520 | |
CWIP | 6 | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
146 | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | 361 | |
Total Assets | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
15 | 7 | -13 | 19 | 65 | 15 | 168 | -8 | 24 | 75 | 10 | -8 | |
-19 | -19 | -17 | -18 | -49 | -52 | -74 | -73 | -104 | -113 | -135 | -15 | |
3 | 12 | 31 | -1 | -18 | 37 | -95 | 81 | 80 | 38 | 125 | 24 | |
Net Cash Flow | -1 | -0 | 2 | 1 | -3 | -0 | 0 | 0 | 0 | -0 | -0 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 91 | 142 | 126 | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 | 141 |
Inventory Days | 192 | 147 | 177 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 | 196 |
Days Payable | 114 | 179 | 169 | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 | 100 |
Cash Conversion Cycle | 168 | 109 | 134 | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 | 237 |
Working Capital Days | 125 | 125 | 142 | 154 | 115 | 147 | 77 | 101 | 163 | 175 | 234 | 237 |
ROCE % | 11% | 20% | 12% | 20% | 22% | 20% | 20% | 22% | 22% | 8% | -4% | -13% |
Documents
Announcements
- Record Date For Rights Issue 1d
-
Corporate Action-Outcome of Right issue
1d - Astec LifeSciences approves Rs. 249.35 Cr Rights Issue at Rs. 890/share, opening 14 July 2025.
-
Announcement under Regulation 30 (LODR)-Raising of Funds
1d - Astec LifeSciences approves Rs.249.35 Cr Rights Issue at Rs.890/share, opening 14 July 2025.
-
Board Meeting Outcome for Outcome Of The Meeting Held On Monday, June 30, 2025.
1d - Astec LifeSciences approves Rs. 250 Cr Rights Issue at Rs. 890/share, record date 4 July 2025.
- Closure of Trading Window 27 Jun
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2022TranscriptPPT
-
Nov 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Feb 2021TranscriptPPT
Product Portfolio
The company offers a range of products and intermediates, including fungicides, insecticides, herbicides, and various chemical compounds, serving global customers and including triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, fluorinated compounds, halides, intermediates, ketones, ethers, alcohols, and many others. [1]